health

people-are-seizing,-being-intubated-after-eating-microdose-chocolates

People are seizing, being intubated after eating microdose chocolates

Yikes —

“Extreme caution” urged as at least 8 people in 4 states sickened, 6 hospitalized.

A Diamond Shruumz chocolate bar, which come in a variety of flavors.

Enlarge / A Diamond Shruumz chocolate bar, which come in a variety of flavors.

Various federal and state health officials are sounding the alarm on Diamond Shruumz-brand Microdosing Chocolate Bars. The candy, said to be infused with mushrooms, has been linked to severe illnesses, including seizures, loss of consciousness, confusion, sleepiness, agitation, abnormal heart rates, hyper/hypotension, nausea, and vomiting, according to an outbreak alert released by the Food and Drug Administration on Friday.

So far, eight people across four states have been sickened—four in Arizona, two in Indiana, one in Nevada, and one in Pennsylvania, the FDA reported. Of the eight, six have been hospitalized.

“We are urging the public to use extreme caution due to the very serious effects of these products,” Maureen Roland, director of the Banner Poison and Drug Information Center in Phoenix, said in a press release earlier this week.

Steve Dudley, director of the Arizona Poison and Drug Information Center, added that there’s “clearly something toxic occurring” with the chocolates. “We’ve seen the same phenomenon of people eating the chocolate bar then seizing, losing consciousness, and having to be intubated.” Dudley noted that the state is aware of additional cases beyond the eight reported Friday by the FDA. Those cases were reported from Nebraska and Utah.

It’s not entirely clear what is in the chocolates or what could be causing the illnesses. The FDA said it was working with the Centers for Disease Control and Prevention as well as America’s Poison Centers to “determine the cause of these illnesses and is considering the appropriate next steps.”

On its website, Diamond Shruumz says that its chocolate bars contain a “primo proprietary blend of nootropic and functional mushrooms.” The website also contains reports of laboratory analyses on their products, some of which indicate the absence of select known fungal toxins and compounds such as the hallucinogen psilocybin and cannabinoids.

Diamond Shruumz did not immediately respond to Ars’ request for comment.

The chocolate bars are still available for sale online but the FDA said that consumers should not eat, sell, or serve them. Any bars already purchased should be discarded. Likewise, retailers should not sell or distribute them. The FDA noted that, in addition to being available online, the bars are also sold in various retail locations nationwide, including smoke/vape shops and retailers that sell hemp-derived products.

People are seizing, being intubated after eating microdose chocolates Read More »

ars-chats-with-precision,-the-brain-chip-maker-taking-the-road-less-invasive

Ars chats with Precision, the brain-chip maker taking the road less invasive

Brain-chip buzz —

Precision tested its BCI on 14 people so far. Two more are scheduled this month.

Precision’s Layer 7 Cortical Interface array.

Enlarge / Precision’s Layer 7 Cortical Interface array.

Work toward brain-computer interfaces has never been more charged. Though neuroscientists have toiled for decades to tap directly into human thoughts, recent advances have the field buzzing with anticipation—and the involvement of one polarizing billionaire has drawn a new level of attention.

With competition amping up in this space, Ars spoke with Ben Rapoport, who is a neurosurgeon, electrical engineer, and co-founder of the brain-computer interface (BCI) company Precision Neuroscience. Precision is at the forefront of the field, having placed its BCI on the brains of 14 human patients so far, with two more scheduled this month. Rapoport says he hopes to at least double that number of human participants by the end of this year. In fact, the 3-year-old company expects to have its first BCI on the market next year.

In addition to the swift progress, Precision is notable for its divergence from its competitor’s strategies, namely Neuralink, the most high-profile BCI company and headed by Elon Musk. In 2016, Rapoport co-founded Neuralink alongside Musk and other scientists. But he didn’t stay long and went on to co-found Precision in 2021. In previous interviews, Rapoport suggested his split from Neuralink related to the issues of safety and invasiveness of the BCI design. While Neuralink’s device is going deeper into the brain—trying to eavesdrop on neuron signals with electrodes at close range to decode thoughts and intended motions and speech—Precision is staying at the surface, where there is little to no risk of damaging brain tissue.

Shallow signals

“It used to be thought that you needed to put needle-like electrodes into the brain surface in order to listen to signals of adequate quality,” Rapoport told Ars. Early BCIs developed decades ago used electrode arrays with tiny needles that sink up to 1.5 millimeters into brain tissue. Competitors such as Blackrock Neurotech and Paradromics are still developing such designs. (Another competitor, Synchron, is developing a stent-like device threaded into a major blood vessel in the brain.) Meanwhile, Neuralink is going deeper, using a robot to surgically implant electrodes into brain tissue, reportedly between 3 mm and 8 mm deep.

However, Rapoport eschews this approach. Anytime something essentially cuts into the brain, there’s damage, he notes. Scar tissue and fibrous tissue can form—which is bad for the patient and the BCI’s functioning. “So, there’s not infinite scalability [to such designs],” Rapoport notes, “because when you try to scale that up to making lots of little penetrations into the brain, at some point you can run into a limitation to how many times you can penetrate the brain without causing irreversible and undetectable damage.”

Further, he says, penetrating the brain is just unnecessary. Rapoport says there is no fundamental data that suggests that penetration is necessary for BCIs advances. Rather, the idea was based on the state of knowledge and technology from decades ago. “It was just that it was an accident that that’s how the field got started,” he said. But, since the 1970s, when centimeter-scale electrodes were first being used to capture brain activity, the technology has advanced from the macroscopic to microscopic range, creating more powerful devices.

“All of conscious thought—movement, sensation, intention, vision, etc.—all of that is coordinated at the level of the neocortex, which is the outermost two millimeters of the brain,” Rapoport said. “So, everything, all of the signals of interest—the cognitive processing signals that are interesting to the brain-computer interface world—that’s all happening within millimeters of the brain surface … we’re talking about very small spatial scales.” With the more potent technology of today, Precision thinks it can collect the data it needs without physically traversing those tiny distances.

Ars chats with Precision, the brain-chip maker taking the road less invasive Read More »

surgeons-remove-pig-kidney-transplant-from-woman

Surgeons remove pig kidney transplant from woman

Interspecies —

No rejection, just a matter of blood flow.

Transplant team

Courtesy of NYU Langone

Surgeons in New York have removed a pig kidney less than two months after transplanting it into Lisa Pisano, a 54-year-old woman with kidney failure who also needed a mechanical heart pump. The team behind the transplant says there were problems with the heart pump, not the pig kidney, and that the patient is in stable condition.

Pisano was facing heart and kidney failure and required routine dialysis. She wasn’t eligible to receive a traditional heart and kidney transplant from a human donor because of several chronic medical conditions that reduced the likelihood of a good outcome.

Pisano first received a heart pump at NYU Langone Health on April 4, followed by the pig kidney transplant on April 12. The heart pump, a device called a left ventricular assist device or LVAD, is used in patients who are either awaiting heart transplantation or otherwise aren’t a candidate for a heart transplant.

In a statement provided to WIRED, Pisano’s medical team explained that they electively removed the pig kidney on May 29—47 days after transplant—after several episodes of the heart pump not being able to pass enough blood through the transplanted kidney. Steady blood flow is important so that the kidney can produce urine and filter waste. Without it, Pisano’s kidney function began to decline.

“On balance, the kidney was no longer contributing enough to justify continuing the immunosuppression regimen,” said Robert Montgomery, director of the NYU Langone Transplant Institute, in the statement. Like traditional transplant patients, Pisano needed to take immunosuppressive drugs to prevent her immune system from rejecting the donor organ.

The kidney came from a pig genetically engineered by Virginia biotech company Revivicor to lack a gene responsible for the production of a sugar known as alpha-gal. In previous studies at NYU Langone, researchers found that removing this sugar prevented immediate rejection of the organ when transplanted into brain-dead patients. During Pisano’s surgery, the donor pig’s thymus gland, which is responsible for “educating” the immune system, was also transplanted to reduce the likelihood of rejection.

A recent biopsy did not show signs of rejection, but Pisano’s kidney was injured due to a lack of blood flow, according to the statement. The team plans to study the explanted pig kidney to learn more.

Pisano is now back on dialysis, a treatment for kidney-failure patients, and her heart pump is still functioning. She would not have been a candidate for the heart pump if she had not received the pig kidney.

“We are hoping to get Lisa back home to her family soon,” Montgomery said, calling Pisano a “pioneer and a hero in the effort to create a sustainable option for people waiting for an organ transplant.”

Pisano was the second living person to receive a kidney from a genetically engineered pig. The first, Richard Slayman of Massachusetts, died in May just two months after the historic transplant. The surgery was carried out on March 16 at Massachusetts General Hospital. In a statement released on May 11, the hospital said it had “no indication” that Slayman’s death was the result of the pig kidney transplant. The donor pig used in Slayman’s procedure had a total of 69 different genetic edits.

The global donor organ shortage has led researchers including the NYU and Massachusetts teams to pursue the possibility of using pigs as an alternative source. But the body immediately recognizes pig tissue as foreign, so scientists are using gene editing in an effort to make pig organs look more like human ones to the immune system. Just how many gene edits will be needed to keep pig organs working in people is a topic of much debate.

Pig heart transplants have also been carried out in two individuals—one in 2022 and the other in 2023—at the University of Maryland. In both cases, the patients were not eligible for human ones. Those donor pigs had 10 genetic edits and were also bred by Revivcor. Both recipients died around two months after their transplants.

This story originally appeared on wired.com.

Surgeons remove pig kidney transplant from woman Read More »

to-pee-or-not-to-pee?-that-is-a-question-for-the-bladder—and-the-brain

To pee or not to pee? That is a question for the bladder—and the brain

💦

The basic urge to pee is surprisingly complex and can go awry as we age.

Cut view of man covering urine with hands. He has some pain and problem. Isolated on striped and blue background

You’re driving somewhere, eyes on the road, when you start to feel a tingling sensation in your lower abdomen. That extra-large Coke you drank an hour ago has made its way through your kidneys into your bladder. “Time to pull over,” you think, scanning for an exit ramp.

To most people, pulling into a highway rest stop is a profoundly mundane experience. But not to neuroscientist Rita Valentino, who has studied how the brain senses, interprets, and acts on the bladder’s signals. She’s fascinated by the brain’s ability to take in sensations from the bladder, combine them with signals from outside of the body, like the sights and sounds of the road, then use that information to act—in this scenario, to find a safe, socially appropriate place to pee. “To me, it’s really an example of one of the beautiful things that the brain does,” she says.

Scientists used to think that our bladders were ruled by a relatively straightforward reflex—an “on-off” switch between storing urine and letting it go. “Now we realize it’s much more complex than that,” says Valentino, now director of the division of neuroscience and behavior at the National Institute of Drug Abuse. An intricate network of brain regions that contribute to functions like decision-making, social interactions, and awareness of our body’s internal state, also called interoception, participates in making the call.

In addition to being mind-bogglingly complex, the system is also delicate. Scientists estimate, for example, that more than 1 in 10 adults have overactive bladder syndrome—a common constellation of symptoms that includes urinary urgency (the sensation of needing to pee even when the bladder isn’t full), nocturia (the need for frequent nightly bathroom visits) and incontinence. Although existing treatments can improve symptoms for some, they don’t work for many people, says Martin Michel, a pharmacologist at Johannes Gutenberg University in Mainz, Germany, who researches therapies for bladder disorders. Developing better drugs has proven so challenging that all major pharmaceutical companies have abandoned the effort, he adds.

Recently, however, a surge of new research is opening the field to fresh hypotheses and treatment approaches. Although therapies for bladder disorders have historically focused on the bladder itself, the new studies point to the brain as another potential target, says Valentino. Combined with studies aimed at explaining why certain groups, such as post-menopausal women, are more prone to bladder problems, the research suggests that we shouldn’t simply accept symptoms like incontinence as inevitable, says Indira Mysorekar, a microbiologist at Baylor College of Medicine in Houston. We’re often told such problems are just part of getting old, particularly for women—“and that’s true to some extent,” she says. But many common issues are avoidable and can be treated successfully, she says: “We don’t have to live with pain or discomfort.”

A delicate balance

The human bladder is, at the most basic level, a stretchy bag. To fill to capacity—a volume of 400 to 500 milliliters (about 2 cups) of urine in most healthy adults—it must undergo one of the most extreme expansions of any organ in the human body, expanding roughly sixfold from its wrinkled, empty state.

To stretch that far, the smooth muscle wall that wraps around the bladder, called the detrusor, must relax. Simultaneously, sphincter muscles that surround the bladder’s lower opening, or urethra, must contract, in what scientists call the guarding reflex.

It’s not just sensory neurons (purple) that can detect stretch, pressure, pain and other sensations in the bladder. Other types of cells, like the umbrella-shaped cells that form the urothelium’s barrier against urine, can also sense and respond to mechanical forces — for example, by releasing chemical signaling molecules such as adenosine triphosphate (ATP) as the organ expands to fill with urine.

Enlarge / It’s not just sensory neurons (purple) that can detect stretch, pressure, pain and other sensations in the bladder. Other types of cells, like the umbrella-shaped cells that form the urothelium’s barrier against urine, can also sense and respond to mechanical forces — for example, by releasing chemical signaling molecules such as adenosine triphosphate (ATP) as the organ expands to fill with urine.

Filling or full, the bladder spends more than 95 percent of its time in storage mode, allowing us to carry out our daily activities without leaks. At some point—ideally, when we decide it’s time to pee—the organ switches from storage to release mode. For this, the detrusor muscle must contract forcefully to expel urine, while the sphincter muscles surrounding the urethra simultaneously relax to let urine flow out.

For a century, physiologists have puzzled over how the body coordinates the switch between storage and release. In the 1920s, a surgeon named Frederick Barrington, of University College London, went looking for the on-off switch in the brainstem, the lowermost part of the brain that connects with the spinal cord.

Working with sedated cats, Barrington used an electrified needle to damage slightly different areas in the pons, part of the brainstem that handles vital functions like sleeping and breathing. When the cats recovered, Barrington noticed that some demonstrated a desire to urinate—by scratching, circling, or squatting—but were unable to voluntarily go. Meanwhile, cats with lesions in a different part of the pons seemed to have lost any awareness of the need to urinate, peeing at random times and appearing startled whenever it happened. Clearly, the pons served as an important command center for urinary function, telling the bladder when to release urine.

To pee or not to pee? That is a question for the bladder—and the brain Read More »

fda’s-review-of-mdma-for-ptsd-highlights-study-bias-and-safety-concerns

FDA’s review of MDMA for PTSD highlights study bias and safety concerns

Complicated —

FDA advisors will meet June 4 to discuss and vote on the therapy’s effectiveness.

MDMA is now in the FDA's hands.

Enlarge / MDMA is now in the FDA’s hands.

The safety and efficacy data on the use of MDMA (aka ecstasy) for post-traumatic stress disorder therapy is “challenging to interpret,” the Food and Drug Administration said in a briefing document posted Friday. The agency noted significant flaws in the design of the underlying clinical trials as well as safety concerns for the drug, particularly cardiovascular harms.

On Tuesday, June 4, the FDA will convene an advisory committee that will review the evidence and vote on MDMA’s efficacy and whether its benefits outweigh its risks. The FDA does not have to follow the committee’s recommendations, but it often does. If the FDA subsequently approves MDMA as part of treatment for PTSD, it would mark a significant shift in the federal government’s stance on MDMA, as well as psychedelics, generally. Currently, the US Drug Enforcement Administration considers MDMA a Schedule I drug, defined as one with “no currently accepted medical use and a high potential for abuse.” It would also offer a new treatment option for patients with PTSD, a disabling psychiatric condition with few treatment options currently.

As Ars has reported previously, the submission of MDMA for approval is based on two clinical trials. The first trial, published in Nature Medicine in 2021, involved 90 participants with moderate PTSD and found that MDMA-assisted psychotherapy significantly improved Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scores compared with participants who were given psychotherapy along with a placebo. In the second study, published in September in Nature Medicine, the finding held up among 104 participants with moderate or severe PTSD (73 percent had severe PTSD).

In the briefing documents released Friday, the FDA highlighted that there was a high potential for bias to have crept into those results. Though the trials were designed to be double-blind (meaning that therapists and trial participants were not told who received MDMA), the FDA noted that MDMA “produces profound alterations in mood, sensation, suggestibility, and cognition.” Blinding is “nearly impossible,” the FDA wrote.  And indeed, approximately 90 percent of those assigned to take MDMA and 75 percent of those assigned to a placebo were able to accurately guess their treatment assignment, the FDA notes. As such, it is “reasonable to assume” that bias and “expectation bias” affected the results of the trials, the FDA concluded.

The agency also noted concerns that MDMA caused “significant increases in blood pressure and pulse,” which could trigger cardiac events, such as heart attacks. However, the trial data was limited for assessing the risks of these adverse events.

The FDA also dinged the studies for not including data on whether participants experienced effects such as “euphoria” after taking MDMA—an anticipated effect that could indicate the drug’s potential for abuse.

In all, the FDA’s review presented a complicated picture of MDMA’s risk-benefit assessment, one that should make for an interesting discussion Tuesday. The FDA’s criticisms follows an even more critical report released earlier this month by the Institute for Clinical and Economic Review (ICER), which identified “substantial concerns about the validity of the results” from the clinical trials.

Like the FDA, ICER found the trials to be “essentially unblinded.” However, ICER went further, having conducted a number of interviews with trial participants and others involved, finding that the trials largely pulled from an existing community of psychedelic advocates and supporters, introducing significant bias. “Concerns have been raised by some that therapists encouraged favorable reports by patients and discouraged negative reports by patients including discouraging reports of substantial harms, potentially biasing the recording of benefits and harms,” the report said. MDMA is known to induce confusion, depression, and paranoia in some. One participant reported feeling “relentlessly suicidal” after the trial, as a result of participating in it, but that result was not reflected in the trial’s reported results.

Various people told ICER that the community involved in the trials regarded psychedelics “more like a religious movement than like pharmaceutical products.” Some participants felt as though “they could be shunned if they reported bad outcomes or that it could lead to future patients being denied the benefits of MDMA-AP.”

In all, ICER concluded that the evidence available to assess for MDMA treatment is “insufficient.”

Editor’s Note: This story was corrected to report that the participant’s suicidal thoughts occurred after the trial, as a result of participation, not during the trial.

FDA’s review of MDMA for PTSD highlights study bias and safety concerns Read More »

modern-lives-are-messing-up-menstrual-cycles—earlier-starts,-more-irregularity

Modern lives are messing up menstrual cycles—earlier starts, more irregularity

downward trend —

Earlier and irregular periods are both linked to poor health outcomes.

Panty liners, hygienic tampons, and sanitary pads.

Enlarge / Panty liners, hygienic tampons, and sanitary pads.

People in the US are starting their menstrual cycles earlier and experiencing more irregularities, both of which raise the risk of a host of health problems later in life, according to an Apple women’s health study looking at data from over 70,000 menstruating iPhone users born between 1950 and 2005.

The mean age of people’s first period fell from 12.5 years in participants born between 1950 and 1969 to 11.9 years in participants born between 2000 and 2005, with a steady decline in between, the study found. There were also notable changes in the extremes—between 1950 and 2005, the percentage of people who started their periods before age 11 rose from 8.6 percent to 15.5 percent. And the percentage of people who started their periods late (at age 16 or above) dropped from 5.5 percent to 1.7 percent.

In addition to periods shifting to earlier starting ages, menstrual cycles also appeared to become more irregular. For this, researchers looked at how quickly people settled into a regular cycle after the start of their period. Between 1950 and 2005, the percentage of people obtaining regularity within two years fell from 76.3 percent to 56 percent.

The study, published by researchers at Apple and Harvard in the journal JAMA Network Open, notes that both of these findings bode poorly for long-term health. Early starting age of menstrual cycles is linked to adverse health outcomes, including cardiovascular diseases, cancers, spontaneous abortion, and premature death, the researchers write. And a longer time to regularity is linked to fertility problems, longer menstrual cycles, and an increased risk of metabolic conditions and all-cause mortality.

Looking across race and ethnicity categories, researchers found that the trends affected all groups. However, Black and Hispanic participants had consistently earlier menstrual starting ages than white and Asian participants. Black participants also saw a larger magnitude shift toward earlier starting ages compared with white participants.

It’s unclear what’s driving the menstrual changes, but the authors speculate that there could be a multitude of factors. The most prominent potential factor is childhood obesity, which has increased in the US over the course of the study period and is known to be linked to earlier puberty. However, the authors note that obesity doesn’t explain the totality of the shifts—an exploratory analysis indicated that obesity only accounted for 46 percent of the trends seen in the study. And other studies have indicated that the shift toward earlier menstrual cycles began before the upward trend of obesity in the US.

The authors of the current study point to various potential environmental factors, including endocrine-disrupting chemicals, metals, air pollutants, dietary patterns, psychosocial stress, and adverse childhood experiences.

The study has limitations, of course, including that it relied on self-reported data and was limited to people who own iPhones, who generally skew toward higher socioeconomic status. Thus, the findings may not be generalizable to the population overall. Still, the data fits with other studies, and the researchers called for more awareness among health care practitioners and more studies to look at trends and health outcomes.

Modern lives are messing up menstrual cycles—earlier starts, more irregularity Read More »

as-bird-flu-spreads-in-cows,-us-close-to-funding-moderna’s-mrna-h5-vaccine

As bird flu spreads in cows, US close to funding Moderna’s mRNA H5 vaccine

New jab —

If trials are successful, US government likely to buy doses for vaccine stockpile.

Testing for bird flu, conceptual image

Digicom Photo/Science Photo Library via Getty

The US government is nearing an agreement to bankroll a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, hoping to bolster its pandemic jab stockpile as an H5N1 outbreak spreads through egg farms and among cattle herds.

The federal funding from the government’s Biomedical Advanced Research and Development Authority, known as BARDA, could come as early as next month, according to people close to the discussions.

It is expected to total several tens of millions of dollars and could be accompanied by a commitment to procure doses if the phase-three trials are successful, they said.

Talks between the government and Pfizer over supporting the development of its mRNA vaccine targeting the H5 family of viruses are also ongoing. Pfizer, like Moderna, played a pivotal role in supplying mRNA vaccines for Washington’s jab rollout during the COVID-19 pandemic.

Bird flu has been detected on poultry farms in 48 states and in dairy cow herds across nine states as part of one of the worst outbreaks in recent history, according to the US Centers for Disease Control and Prevention. The CDC has also reported two cases affecting dairy workers in recent months, adding to concerns of the virus spreading in human populations.

US health authorities continue to classify the public health risk from bird flu as low, but their efforts to build up and diversify the pandemic vaccine stockpile have gathered pace. Federal health officials said last week that the government was moving ahead with plans to fill 4.8 million vials from its existing portfolio of protein-based bird flu vaccines and was in discussions with Moderna and Pfizer.

The possibility of contributing to the US pandemic vaccine stockpile also represents a commercial opportunity for the mRNA vaccine makers, whose market valuations have fallen significantly from pandemic highs. Moderna’s share price is up nearly 37 percent since the start of April.

Moderna has completed dosing of a mid-stage trial of its H5 pandemic flu vaccine, with interim data expected soon. Pfizer said in a statement on Wednesday that it “would be prepared to deploy the company’s capabilities to develop a vaccine for strategic stockpiles,” confirming that it had launched a phase-one trial for a pandemic flu vaccine last December.

Applications for BARDA grant funding for an mRNA-based pandemic flu vaccine closed in December last year, according to a project proposal seen by the Financial Times. But the bird flu outbreak has increased the urgency of talks, with federal officials acknowledging that the speed with which mRNA vaccines were designed and deployed during the COVID-19 pandemic showed their value compared with more traditional vaccine technology.

The jabs from GSK, Sanofi, and CSL Seqirus, which make up the US government’s existing pandemic vaccine portfolio, provide immunity to the current strain of bird flu, according to laboratory testing, but rely on a more time-intensive manufacturing process using egg- and cell-based cultures.

The US health department, Moderna, and Pfizer declined to comment on the potential funding.

© 2024 The Financial Times Ltd. All rights reserved. Not to be redistributed, copied, or modified in any way.

As bird flu spreads in cows, US close to funding Moderna’s mRNA H5 vaccine Read More »

“deny,-denounce,-delay”:-the-battle-over-the-risk-of-ultra-processed-foods

“Deny, denounce, delay”: The battle over the risk of ultra-processed foods

A shopping cart by a store shelf in a supermarket

When the Brazilian nutritional scientist Carlos Monteiro coined the term “ultra-processed foods” 15 years ago, he established what he calls a “new paradigm” for assessing the impact of diet on health.

Monteiro had noticed that although Brazilian households were spending less on sugar and oil, obesity rates were going up. The paradox could be explained by increased consumption of food that had undergone high levels of processing, such as the addition of preservatives and flavorings or the removal or addition of nutrients.

But health authorities and food companies resisted the link, Monteiro tells the FT. “[These are] people who spent their whole life thinking that the only link between diet and health is the nutrient content of foods … Food is more than nutrients.”

Monteiro’s food classification system, “Nova,” assessed not only the nutritional content of foods but also the processes they undergo before reaching our plates. The system laid the groundwork for two decades of scientific research linking the consumption of UPFs to obesity, cancer, and diabetes.

Studies of UPFs show that these processes create food—from snack bars to breakfast cereals to ready meals—that encourages overeating but may leave the eater undernourished. A recipe might, for example, contain a level of carbohydrate and fat that triggers the brain’s reward system, meaning you have to consume more to sustain the pleasure of eating it.

In 2019, American metabolic scientist Kevin Hall carried out a randomized study comparing people who ate an unprocessed diet with those who followed a UPF diet over two weeks. Hall found that the subjects who ate the ultra-processed diet consumed around 500 more calories per day, more fat and carbohydrates, less protein—and gained weight.

The rising concern about the health impact of UPFs has recast the debate around food and public health, giving rise to books, policy campaigns, and academic papers. It also presents the most concrete challenge yet to the business model of the food industry, for whom UPFs are extremely profitable.

The industry has responded with a ferocious campaign against regulation. In part it has used the same lobbying playbook as its fight against labeling and taxation of “junk food” high in calories: big spending to influence policymakers.

FT analysis of US lobbying data from non-profit Open Secrets found that food and soft drinks-related companies spent $106 million on lobbying in 2023, almost twice as much as the tobacco and alcohol industries combined. Last year’s spend was 21 percent higher than in 2020, with the increase driven largely by lobbying relating to food processing as well as sugar.

In an echo of tactics employed by cigarette companies, the food industry has also attempted to stave off regulation by casting doubt on the research of scientists like Monteiro.

“The strategy I see the food industry using is deny, denounce, and delay,” says Barry Smith, director of the Institute of Philosophy at the University of London and a consultant for companies on the multisensory experience of food and drink.

So far the strategy has proved successful. Just a handful of countries, including Belgium, Israel, and Brazil, currently refer to UPFs in their dietary guidelines. But as the weight of evidence about UPFs grows, public health experts say the only question now is how, if at all, it is translated into regulation.

“There’s scientific agreement on the science,” says Jean Adams, professor of dietary public health at the MRC Epidemiology Unit at the University of Cambridge. “It’s how to interpret that to make a policy that people aren’t sure of.”

“Deny, denounce, delay”: The battle over the risk of ultra-processed foods Read More »

family-stricken-with-rare-brain-worms-after-eating-undercooked-bear

Family stricken with rare brain worms after eating undercooked bear

Unbearably gross —

In the parasite vs. bear vs. human battle, the grizzly parasite comes out on top.

American black bear seen along the Red Rock Parkway inside Waterton Lakes National Park in Alberta, Canada.

Enlarge / American black bear seen along the Red Rock Parkway inside Waterton Lakes National Park in Alberta, Canada.

In the summer of 2022, a family gathered in South Dakota for a reunion that included a special meal—kabobs made with the meat of a black bear that one of the family members had “harvested” from northern Saskatchewan, Canada, that May. Lacking a meat thermometer, the family assessed the doneness of the dark-colored meat by eye. At first, they accidentally served it rare, which a few family members noticed before a decision was made to recook it. The rest of the reunion was unremarkable, and the family members departed to their homes in Arizona, Minnesota, and South Dakota.

But just days later, family members began falling ill. One, a 29-year-old male in Minnesota, sought care for a mysterious illness marked by fever, severe muscle pains, swelling around his eyes (periorbital edema), high levels of infection-fighting white blood cells (eosinophilia, a common response to parasites), and other laboratory anomalies. The man sought care four times and was hospitalized twice in a 17-day span in July. It wasn’t until his second hospitalization that doctors learned about the bear meat—and then it all made sense.

The doctors suspected the man had a condition called trichinellosis and infection of Trichinella nematodes (roundworms). These dangerous parasites can be found worldwide, embedded into the muscle fibers of various carnivores and omnivores, according to the Centers for Disease Control and Prevention. But, it’s quite rare to find them in humans in North America. Between 2016 and 2022, there were seven outbreaks of trichinellosis in the US, involving just 35 cases. The majority were linked to eating bear meat, but moose and wild boar meat are also common sources.

Trichinella nativa infections—Arizona, Minnesota, and South Dakota, 2022.” height=”396″ src=”https://cdn.arstechnica.net/wp-content/uploads/2024/05/mm7320a2-F-large-640×396.webp” width=”640″>

Enlarge / Microscopic examination of encapsulated larvae in a direct black bear meat muscle squash prep (A), larvae liberated from artificially digested bear meat (B), and motile larvae viewed with differential interference contrast microscopy (C and D)from black bear meat suspected as the source of an outbreak of human Trichinella nativa infections—Arizona, Minnesota, and South Dakota, 2022.

Once eaten, larvae encased in the meat are released and begin to invade the small intestines (the gastrointestinal phase), causing pain, diarrhea, nausea, and vomiting. Then, the larvae develop into adults in the gut, mate, and produce more larvae there. The second generation of worms then go wandering through the lymphatic system, into the blood, and then throughout the body (systemic phase). The larvae can end up all over, reaching skeletal muscles, the heart, and the brain, which is rich in oxygen. The systemic phase is marked by fever, periorbital edema, muscle pain, heart inflammation, and brain inflammation. The larvae can also provoke severe eosinophilia, particularly when they move into the heart and central nervous system.

The man’s symptoms fit the case, and several tests confirmed the parasitic infection. Of eight interviewed family members present for the bear-meat meal, six people had illnesses matching trichinellosis (ranging in age from 12 to 62), and three of them were hospitalized, including the 12-year-old. Four of the six sickened people had eaten the bear meat, while two only ate vegetables that were cooked alongside the meat and cross-contaminated. Experts at the CDC obtained leftover frozen samples of the bear meat, which revealed moving larvae. Testing identified the worm as Trichinella nativa, a species that is resistant to freezing.

In an outbreak study published Thursday in the CDC’s Morbidity and Mortality Weekly Report, health officials from Minnesota and the CDC reported that the three hospitalized patients were treated with the anti-parasitic drug albendazole and recovered. The remaining three cases fortunately recovered without treatment. The health experts noted how tricky it can be to identify and diagnose these rare cases but flagged periorbital edema and the eosinophilia as being key clinical clues to the grizzly infections. And, above all, people who are going to eat wild game meat should invest in a meat thermometer and make sure the meat is cooked to at least ≥165° F (≥74° C) to avoid risking brain worms.

Family stricken with rare brain worms after eating undercooked bear Read More »

new-research-shows-gas-stove-emissions-contribute-to-19,000-deaths-annually

New research shows gas stove emissions contribute to 19,000 deaths annually

New research shows gas stove emissions contribute to 19,000 deaths annually

Ruth Ann Norton used to look forward to seeing the blue flame that danced on the burners of her gas stove. At one time, she says, she would have sworn that preparing meals with the appliance actually made her a better cook.

But then she started learning about the toxic gasses, including carbon monoxide, formaldehyde and other harmful pollutants that are emitted by stoves into the air, even when they’re turned off.

“I’m a person who grew up cooking, and love that blue flame,” said Norton, who leads the environmental advocacy group known as the Green & Healthy Homes Initiative. “But people fear what they don’t know. And what people need to understand really strongly is the subtle and profound impact that this is having—on neurological health, on respiratory health, on reproductive health.”

In recent years, gas stoves have been an unlikely front in the nation’s culture wars, occupying space at the center of a debate over public health, consumer protection, and the commercial interests of manufacturers. Now, Norton is among the environmental advocates who wonder if a pair of recent developments around the public’s understanding of the harms of gas stoves might be the start of a broader shift to expand the use of electrical ranges.

On Monday, lawmakers in the California Assembly advanced a bill that would require any gas stoves sold in the state to bear a warning label indicating that stoves and ovens in use “can release nitrogen dioxide, carbon monoxide, and benzene inside homes at rates that lead to concentrations exceeding the standards of the Office of Environmental Health Hazard Assessment and the United States Environmental Protection Agency for outdoor air quality.”

The label would also note that breathing those pollutants “can exacerbate preexisting respiratory illnesses and increase the risk of developing leukemia and asthma, especially in children. To help reduce the risk of breathing harmful gases, allow ventilation in the area and turn on a vent hood when gas-powered stoves and ranges are in use.”

The measure, which moved the state Senate, could be considered for passage later this year.

“Just running a stove for a few minutes with poor ventilation can lead to indoor concentrations of nitrogen dioxide that exceed the EPA’s air standard for outdoors,” Gail Pellerin, the California assembly member who introduced the bill, said in an interview Wednesday. “You’re sitting there in the house drinking a glass of wine, making dinner, and you’re just inhaling a toxic level of these gases. So, we need a label to make sure people are informed.”

Pellerin’s proposal moved forward in the legislature just days after a group of Stanford researchers announced the findings of a peer-reviewed study that builds on earlier examinations of the public health toll of exposure to nitrogen dioxide pollution from gas and propane stoves.

New research shows gas stove emissions contribute to 19,000 deaths annually Read More »

“outrageously”-priced-weight-loss-drugs-could-bankrupt-us-health-care

“Outrageously” priced weight-loss drugs could bankrupt US health care

Collision course —

Prices would need to be dramatically slashed to avoid increasing the national deficit.

Packaging for Wegovy, manufactured by Novo Nordisk, is seen in this illustration photo.

Enlarge / Packaging for Wegovy, manufactured by Novo Nordisk, is seen in this illustration photo.

With the debut of remarkably effective weight-loss drugs, America’s high obesity rate and its uniquely astronomical prescription drug pricing appear to be set on a catastrophic collision course—one that threatens to “bankrupt our entire health care system,” according to a new Senate report that modeled the economic impact of the drugs in different uptake scenarios.

If just half of the adults in the US with obesity start taking a new weight-loss drug, such as Wegovy, the collective cost would total an estimated $411 billion per year, the analysis found. That’s more than the $406 billion Americans spent in 2022 on all prescription drugs combined.

While the bulk of the spending on weight-loss drugs will occur in the commercial market—which could easily lead to spikes in health insurance premiums—taxpayer-funded Medicare and Medicaid programs will also see an extraordinary financial burden. In the scenario that half of adults with obesity go on the drug, the cost to those federal programs would total $166 billion per year, rivaling the programs’ total 2022 drug costs of $175 billion.

In all, by 2031, total US spending on prescription drugs is poised to reach over $1 trillion per year due to weight-loss drugs. Without them, the baseline projected spending on all prescription drugs would be just under $600 billion.

The analysis was put together by the Senate’s Health, Education, Labor, and Pensions (HELP) committee, chaired by staunch drug-pricing critic Bernie Sanders (I-Vt). And it’s quick to knock down a common argument about the high prices for smash-hit weight-loss drugs. That is, with their high effectiveness, the drugs will improve people’s health in wide-ranging ways, including controlling diabetes, improving cardiovascular health, and potentially more. And, with those improvements, people won’t need as much health care, generally, lowering health care costs across the board.

But, while the drugs do appear to have wide-ranging, life-altering benefits for overall health, the prices of the drugs are still set too high to be entirely offset by any savings in health care use. The HELP committee analysis cited a March Congressional Budget Office (CBO) report that found: “at their current prices, [anti-obesity medicines] would cost the federal government more than it would save from reducing other health care spending—which would lead to an overall increase in the deficit over the next 10 years.” Moreover, in April, the head of the CBO said that the drugmakers would have to slash prices of their weight-loss drugs by 90 percent to “get in the ballpark” of not increasing the national deficit.

The HELP committee report offered a relatively simple solution to the problem: Drugmakers should set their US prices to match the relatively low prices they’ve set in other countries. The report focused on Wegovy because it currently accounts for the most US prescriptions in the new class of weight-loss drugs (GLP-1 drugs). Wegovy is made by Denmark-based Novo Nordisk.

In the US, the estimated net price (after rebates) of Wegovy is $809 per month. In Denmark, the price is $186 per month. A study by researchers at Yale estimated that drugs like Wegovy can be profitably manufactured for less than $5 per month.

If Novo Nordisk set its US prices for Wegovy to match the Danish price, spending to treat half of US adults with obesity would drop from $411 billion to $94.5 billion, a roughly $316.5 billion savings.

Without a dramatic price cut, Americans will likely face either losing access to the drugs or shouldering higher overall health care costs, or some of both. The HELP committee report highlighted how this recently played out in North Carolina. In January, the board of trustees for the state employee health plan voted to end all coverage of Wegovy and other GLP-1 drugs due to the cost. Estimates found that if the plan continued to cover the drugs, the state would need to nearly double health insurance premiums to offset the costs.

“Outrageously” priced weight-loss drugs could bankrupt US health care Read More »

ultra-spicy-one-chip-challenge-chip-contributed-to-teen’s-death,-report-says

Ultra-spicy One Chip Challenge chip contributed to teen’s death, report says

Tragic —

The high dose of capsaicin paired with a heart defect appear to have contributed.

Ultra-spicy One Chip Challenge chip contributed to teen’s death, report says

An autopsy report of a Massachusetts teen who tragically died hours after eating an ultra-spicy tortilla chip suggested that his death was due to the high dose of spice in the chip and a congenital heart defect, according to reporting by the Associated Press.

Harris Wolobah, a previously healthy 14-year-old from Worcester, died September 1, 2023 hours after eating the chip—a 2023 Paqui One Chip Challenge chip—which were sold individually, wrapped in tin foil, and seasoned with two of hottest peppers in the world, the Naga Viper pepper and the Carolina Reaper pepper. Paqui sold the chip with a challenge in which eaters were dared to consume the chip, wait as long as possible before eating or drinking anything, and post the aftermath on social media, where the challenge went viral.

Harris’ mother, Lois Wolobah, immediately suspected the chip was involved in his untimely death. At the time, she reportedly said she picked him up from school after getting a call from the nurse. He was clutching his stomach and, about two hours later, lost consciousness and was rushed to the hospital, where he died. She reported that he had no known medical conditions at the time.

According to the autopsy report, Harris died of cardiopulmonary arrest “in the setting of recent ingestion of food substance with high capsaicin concentration,” the AP reported. Capsaicin is the compound in peppers that gives them their heat.

The report also noted that Harris had an enlarged heart and a congenital anomaly called “myocardial bridging.” This is a common and generally benign condition in which one or more of the arteries delivering blood to the heart go through the heart’s muscle instead of lying on its surface, according to Stanford Medicine. In Harris’ case, the condition involved his left anterior descending coronary artery. An analysis on the American Academy of Cardiology’s website noted that myocardial bridging is “clinically silent” in the majority of cases.

Dr. James Udelson, chief of cardiology at Tufts Medical Center, confirmed to the AP that the chip could have played a role in the teen’s death. “It is possible that with significant stimulation of the heart, the muscle beyond the bridge suddenly had abnormal blood flow (‘ischemia’) and could have been a cause of a severe arrhythmia,” Udelson told the AP in an email. “There have been reports of acute toxicity with capsaicin causing ischemia of the heart muscle.”

A second expert, Dr. Syed Haider, a cardiologist at MedStar Washington Hospital Center, added to the AP that the large doses of capsaicin can increase how the heart squeezes, putting extra pressure on the artery.

Even if Harris’ heart defect made him more vulnerable to the effects of the chip, other case studies have found dangerous and life-threatening effects of high doses of capsaicin in people without heart anomalies. Ultra-hot peppers have also been linked to conditions in which arteries in the brain constrict, causing thunderclap headaches and neurological symptoms.

Paqui, a subsidiary of Hershey, pulled the chip from the market shortly after Harris’ death.

Ultra-spicy One Chip Challenge chip contributed to teen’s death, report says Read More »